I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 12 studies | 19% ± 4% | |
| CD16-positive, CD56-dim natural killer cell, human | 11 studies | 24% ± 8% | |
| CD16-negative, CD56-bright natural killer cell, human | 8 studies | 21% ± 5% | |
| mast cell | 7 studies | 26% ± 15% | |
| platelet | 7 studies | 31% ± 11% | |
| mature NK T cell | 6 studies | 20% ± 4% | |
| hematopoietic stem cell | 6 studies | 31% ± 10% | |
| retinal ganglion cell | 5 studies | 30% ± 5% | |
| hematopoietic precursor cell | 4 studies | 28% ± 13% | |
| glutamatergic neuron | 4 studies | 38% ± 18% | |
| CD8-positive, alpha-beta T cell | 4 studies | 20% ± 2% | |
| effector memory CD8-positive, alpha-beta T cell | 4 studies | 21% ± 6% | |
| gamma-delta T cell | 4 studies | 23% ± 6% | |
| non-classical monocyte | 3 studies | 22% ± 4% | |
| GABAergic neuron | 3 studies | 40% ± 16% | |
| megakaryocyte | 3 studies | 36% ± 12% | |
| group 3 innate lymphoid cell | 3 studies | 18% ± 3% | |
| double negative thymocyte | 3 studies | 20% ± 1% | |
| T cell | 3 studies | 16% ± 1% |
